NovoCure Ltd (NASDAQ: NVCR) is 18.22% higher on its value in year-to-date trading and has touched a low of $10.87 and a high of $24.74 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NVCR stock was last observed hovering at around $18.10 in the last trading session, with the day’s loss setting it -0.45%.
Currently trading at $17.65, the stock is 5.66% and 6.14% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.0 million and changing -2.49% at the moment leaves the stock 3.92% off its SMA200. NVCR registered 37.14% gain for a year compared to 6-month loss of 9.42%. The firm has a 50-day simple moving average (SMA 50) of $16.6704 and a 200-day simple moving average (SMA200) of $16.96545.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 20.40% gain in the last 1 month and extending the period to 3 months gives it a -5.56%, and is 16.27% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.39% over the week and 7.71% over the month.
NovoCure Ltd (NVCR) has around 1453 employees, a market worth around $1.91B and $577.74M in sales. Profit margin for the company is -25.93%. Distance from 52-week low is 62.37% and -28.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.27%).
NovoCure Ltd quarterly earnings per share for the current quarter are estimated at -0.35 with sales reaching $153.05M over the same period.The EPS is expected to grow by 32.97% this year, but quarterly earnings will post 16.80% year-over-year. Quarterly sales are estimated to grow 14.40% in year-over-year returns.
323.0 institutions hold shares in NovoCure Ltd (NVCR), with institutional investors hold 96.89% of the company’s shares. The shares outstanding are 107.08M, and float is at 97.49M with Short Float at 5.92%. Institutions hold 87.94% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.14 million shares valued at $276.51 million. The investor’s holdings represent 15.0482 of the NVCR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 12.13 million shares valued at $207.83 million to account for 11.3106 of the shares outstanding. The other top investors are CAPITAL INTERNATIONAL INVESTORS which holds 11.7 million shares representing 10.904 and valued at over $200.36 million, while VANGUARD GROUP INC holds 10.3736 of the shares totaling 11.13 million with a market value of $190.61 million.
NovoCure Ltd (NVCR) Insider Activity
The most recent transaction is an insider sale by Paravasthu Mukund, the company’s Chief Operating Officer. SEC filings show that Paravasthu Mukund sold 44 shares of the company’s common stock on Nov 02 ’24 at a price of $16.69 per share for a total of $734.0. Following the sale, the insider now owns 3459.0 shares.
NovoCure Ltd disclosed in a document filed with the SEC on Oct 31 ’24 that Puri Michal Nath (Chief Human Resources Officer) sold a total of 810 shares of the company’s common stock. The trade occurred on Oct 31 ’24 and was made at $15.79 per share for $12792.0. Following the transaction, the insider now directly holds 0.11 million shares of the NVCR stock.
Still, SEC filings show that on Nov 01 ’24, Leonard Frank X (EVP, Pres., Novocure Oncology) disposed off 598 shares at an average price of $15.94 for $9531.0. The insider now directly holds 161,236 shares of NovoCure Ltd (NVCR).
